ClinicalTrials.gg
CompletedNCT02431247Updated Sep 28, 2022Results posted

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

A Phase 3 interventional study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC and DRV/COBI FDC in Immunodeficiency Virus Type 1, Human, sponsored by Janssen Sciences Ireland UC. Completed at 81 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-28.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Janssen Sciences Ireland UC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
725
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC coadministered with Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC in human immunodeficiency virus-1 (HIV-1) infected, antiretroviral (ARV) treatment naive adult participants.

Read the detailed description

This is a Phase 3, multicenter (when more than one hospital or medical school team work on a medical research study), randomized (study drug assigned by chance), double-blind (a medical research study in which neither the researchers nor the participant know what treatment the participant is receiving), active-controlled (study in which the experimental treatment or procedure is compared to a standard [control] treatment or procedure) study. The study consists of 5 periods: a Screening period, Double-blind treatment period, Single-arm treatment period, Extension period and a Follow-up period. Participants will receive either darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) fixed dose combination (D/C/F/TAF FDC) or DRV/COBI FDC along with FTC/TDF FDC. Primarily percentage of participants with human immunodeficiency virus (HIV) -1 Ribonucleic acid (RNA) less than (\<) 50 copies per milliliter (copies/ml) defined by snapshot analysis will be evaluated. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Immunodeficiency Virus Type 1, Human

Browse trials for

Keywords

  • Immunodeficiency Virus Type 1, Human
  • Darunavir
  • Cobicistat
  • Tenofovir Alafenamide
  • Emtricitabine
  • Tenofovir Disoproxil Fumarate
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 725 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Janssen Sciences Ireland UC is the lead sponsor of 29 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of any approved or experimental anti- (anti-HIV) drug for any length of time
  • Screening plasma HIV-1 ribonucleic acid (RNA) level greater than or equal to >=1,000 copies per milliliter (copies/mL)
  • Cluster of Differentiation 4+ (CD4+) cell count >50 cells/microliter (cells/mcL)
  • Screening HIV-1 genotype report must show full sensitivity to DRV, TDF and FTC
  • Screening eGFRcreatinine >=70 mL/min according to the formula for creatinine clearance

Exclusion criteria

Exclusion Criteria:

  • Subject has been diagnosed with a new acquired immunodeficiency syndrome (AIDS)-defining condition within the 30 days prior to screening
  • Subject has proven or suspected acute hepatitis within 30 days prior to screening
  • Subject is or positive
  • Subject has a history of cirrhosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
725 participants (actual)

Study arms

  • Experimental
    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

    Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination \[FDC\]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.

    Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC · Drug: FTC/TDF FDC Matching Placebo · Drug: DRV/COBI FDC Matching Placebo

  • Active comparator
    DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC

    Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.

    Drug: DRV/COBI FDC · Drug: FTC/TDF FDC · Drug: D/C/F/TAF FDC - Matching Placebo

Interventions

  • DrugDarunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC

    Drug pages: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.

  • DrugDRV/COBI FDC

    A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.

  • DrugFTC/TDF FDC

    Drug pages: Emtricitabine · Tenofovir

    A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.

  • DrugD/C/F/TAF FDC - Matching Placebo

    Matching placebo of D/C/F/TAF FDC will be administered once daily.

  • DrugFTC/TDF FDC Matching Placebo

    Matching placebo of FTC/TDF FDC will be administered once daily.

  • DrugDRV/COBI FDC Matching Placebo

    Matching placebo of DRV/COBI FDC will be administered once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach

    Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.

    Time frame: At Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach

    Percentage of participants with HIV-1 RNA \< 20/200 copies per mL using FDA snapshot approach were reported. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48 and 96), 2) virologic failure (HIV RNA \>= 20/50/200 copies per mL at Week 48 and 96), 3) no viral load data in the Week 48 and 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.

    Time frame: At Weeks 48 and 96

  2. Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm

    Percentage of participants with HIV-1 RNA less than (\<) 20, 50, and 200 copies per mL at Weeks 48 and 96 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA \< 50 copies per mL; confirmed HIV-1 RNA \>= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.

    Time frame: At Week 48 and 96

  3. Change From Baseline in log10 HIV-1 RNA Levels at Week 48

    Change from baseline in log10 HIV-1 RNA levels were reported.

    Time frame: Baseline and Week 48

  4. Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48

    The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed.

    Time frame: Baseline and Week 48

  5. Change From Baseline in Serum Creatinine at Week 48

    Change from baseline in serum creatinine at Week 48 was reported.

    Time frame: Baseline and Week 48

  6. Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48

    Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR \[\>=90 mL/min\]); Stage 2 (Mild CKD \[60 to 90 mL/min\]); Stage 3 (Moderate CKD \[30 to 59mL/min\]); Stage 4 (Severe CKD \[15 to 29 mL/min\]); Stage 5 (End Stage CKD \[\<15 mL/min\]). The eGFRcr was assessed by calculating serum creatinine (Scr) using the equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144\*(Scr/0.7)\^-0.329\*0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144\*(Scr/0.7)\^-1.209\*0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-0.411\*0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-1.209\*0.993\^age (Scr \>0.9 mg/dL) for male participants.

    Time frame: Baseline and Week 48

  7. Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48

    Change from baseline in eGFRcr by cockcroft-gault formula at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female.

    Time frame: Baseline and Week 48

  8. Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48

    Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) \>= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[\* 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L).

    Time frame: Baseline and Week 48

  9. Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 48

    AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Up to Weeks 48

  10. Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48

    Change from baseline in UPCR at Week 48 was reported.

    Time frame: Baseline and Week 48

  11. Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48

    Change from baseline in UACR at Week 48 was reported.

    Time frame: Baseline and Week 48

  12. Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48

    Change from baseline in URBPCR at Week 48 were reported.

    Time frame: Baseline and Week 48

  13. Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48

    Change from baseline in UB2MGCR at Week 48 were reported.

    Time frame: Baseline and Week 48

  14. Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48

    Percent change from baseline in FEPO4 at Week 48 was reported.

    Time frame: Baseline and Week 48

  15. Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir

    AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post-dose.

    Time frame: 0 to 24 hours post dose

  16. Predose (Trough) Plasma Concentration (C0h) of Darunavir

    C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.

    Time frame: 30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)

  17. Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide

    The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.

    Time frame: 30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)

  18. Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide

    C0-2h is defined as the plasma concentrations 2 hours after dosing.

    Time frame: 0 to 2 hours post dose

  19. Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)

    The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from baseline in hip and spine BMD was assessed.

    Time frame: Baseline, Weeks 24 and 48

  20. Change From Baseline in BMD T-score of Hip and Spine

    BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5.

    Time frame: Baseline, Weeks 24 and 48

  21. Change From Baseline in Alkaline Phosphatase (ALP) Levels at Weeks 24 and 48

    Change from baseline in ALP at Weeks 24 and 48 was reported.

    Time frame: Baseline, Weeks 24 and 48

  22. Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Weeks 24 and 48

    Change from baseline in serum P1NP at Weeks 24 and 48 were reported.

    Time frame: Baseline, Weeks 24 and 48

  23. Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Weeks 24 and 48

    Change from baseline in serum CTX at Weeks 24 and 48 were reported.

    Time frame: Baseline, Weeks 24 and 48

  24. Change From Baseline in Levels of Parathyroid Hormone (PTH) at Weeks 24 and 48

    Change from baseline in PTH at Weeks 24 and 48 were reported.

    Time frame: Baseline, Weeks 24 and 48

  25. Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48

    Change from baseline in 25-OH Vitamin D levels at Week 24 and 48 were reported.

    Time frame: Baseline, Weeks 24 and 48

  26. Percentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach

    Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 96), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 96), 3) no viral load data in the Week 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.

    Time frame: At Week 96

  27. Change From Reference in log10 HIV-1 RNA Levels at Week 96

    Change from reference in log10 HIV-1 RNA levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for Test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  28. Change From Reference in CD4+ Cell Count at Week 96

    The immunologic change was determined by changes in cluster of differentiation (CD4+) cell count. Change from reference in CD4+ cell count at Week 96 was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  29. Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability

    Treatment adherence assessed by drug accountability (based on pill count) from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study. Adherent participants were defined as having an adherence \>95% as assessed by drug accountability.

    Time frame: Baseline to Switch and switch to EOE to Open-Label D/C/F/TAF (Up to 3 years)

  30. Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 96

    AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Up to Week 96

  31. Change From Reference in Serum Creatinine

    Change from reference in serum creatinine was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  32. Change From Reference in eGFRcr by CKD-EPI Formula

    Change from reference in eGFRcr was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD). The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144 \* (Scr/0.7)\^-0.329 \* 0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144 \* (Scr/0.7)\^-1.209 \* 0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141 x (Scr/0.9)\^-0.411 x 0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141 \* (Scr/0.9)\^-1.209 x 0.993\^age (Scr \>0.9 mg/dL) for male participants. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  33. Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula

    Change from reference in eGFRcr by cockcroft-gault formula was reported. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  34. Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula

    Change from reference in eGFRcyst was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[x 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L). Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  35. Change From Reference in UPCR

    Change from reference in UPCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  36. Change From Reference in UACR

    Change from reference in UACR at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  37. Change From Reference in URBPCR

    Change from reference in URBPCR at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  38. Change From Reference in UB2MGCR

    Change from reference in UB2MGCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  39. Percent Change From Reference in Urine FEPO4

    Percent change from reference in FEPO4 at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  40. Percent Change From Reference in Hip and Spine BMD

    The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DEXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  41. Change From Reference in BMD T-score of Hip and Spine at Week 96

    BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  42. Change From Reference in ALP Levels

    Change from reference in ALP levels at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  43. Change From Reference in Levels of Serum P1NP

    Change from reference in serum P1NP levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  44. Change From Reference in Levels of Serum CTX

    Change from reference in serum CTX levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  45. Change From Reference in Levels of PTH

    Change from reference in PTH levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  46. Change From Reference in Levels of 25-OH Vitamin D

    Change from reference in 25-OH Vitamin D were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  47. Percentage of Participants With HIV RNA <50, <20, and <200 Copies/mL Post-week 96 to End of Extension

    Percentage of participants with HIV RNA \<50, \<20, and \<200 copies/mL post Week 96 to end of extension were reported.

    Time frame: Week 96 to end of extension (up to 3 years)

  48. Percentage of Participants With Protocol-defined Virologic Failure (PDVF)

    Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).

    Time frame: From Baseline up to Week 96

  49. Percentage of Participants With PDVF Post-week 96 to End of Extension

    Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).

    Time frame: Week 96 to end of extension (up to 3 years)

  50. Percentage of Participants With Non-PDVF by Kaplan-Meier Estimates

    Percentage of participants with non-PDVF by Kaplan-Meier Estimates were reported. PDVF was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).

    Time frame: From Week 96 to end of extension (up to 2 years and 6 months)

  51. Percentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates

    Percentage of participants with time to treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic failure or having discontinued for reasons other than alternate access to D/C/F/TAF (or other ARVs).

    Time frame: From Week 96 to end of extension (up to 3 years)

  52. CD4+ Cell Count Post-Week From 96 to End of Extension

    The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.

    Time frame: Week 96 to end of extension (up to 3 years)

  53. Number of Participants With ARV Resistance

    Number of participants with DRV, FTC, TDF/TAF resistance were reported.

    Time frame: Baseline to end of extension (up to 4 years)

  54. Percentage of Participants With Grade 3 and 4 AEs, SAEs, and Premature Discontinuations Due to Adverse Events Post-Week 96 to End of Extension

    AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From Week 96 to end of extension (up to 3 years)

07

Results

Posted Sep 14, 2018

Participant flow

BL to EOE-Test and BL to Switch- Control
Participant flow — BL to EOE-Test and BL to Switch- Control
MilestoneD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF
Started3623630
Completed2963220
Not completed66410
Withdrew: Other1120
Withdrew: Lost to follow-up1780
Withdrew: Physician decision940
Withdrew: Pregnancy110
Withdrew: Adverse event12160
Withdrew: Death010
Withdrew: Withdrawal by subject1490
Withdrew: Subject non-compliant200
Switch to D/C/F/TAF (Until EOE)
Participant flow — Switch to D/C/F/TAF (Until EOE)
MilestoneD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF
Started00322
Completed00289
Not completed0033
Withdrew: Other004
Withdrew: Lost to follow-up0012
Withdrew: Physician decision001
Withdrew: Adverse event005
Withdrew: Death001
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach

Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.

Time frame:
At Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach91.4 ± 88.188.4 ± 84.7
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · Mantel Haenszel · p = < 0.001 (inferiority margin is 10%.) · Difference in percentage: 2.7 · 95% CI -1.6 to 7.1
SecondaryPercentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach

Percentage of participants with HIV-1 RNA \< 20/200 copies per mL using FDA snapshot approach were reported. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48 and 96), 2) virologic failure (HIV RNA \>= 20/50/200 copies per mL at Week 48 and 96), 3) no viral load data in the Week 48 and 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.

Time frame:
At Weeks 48 and 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF
At week 48: <20 Copies per mL82.6 (78.3 to 86.4)79.3 (74.8 to 83.4)—
At week 48: <200 Copies per mL92.8 (89.7 to 95.3)90.6 (87.2 to 93.4)—
At week 96: <20 Copies per mL76.2 (71.5 to 80.5)—83.5 (78.7 to 87.6)
At week 96: <200 Copies per mL86.2 (82.2 to 89.6)—96.9 (94.2 to 98.6)
SecondaryPercentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm

Percentage of participants with HIV-1 RNA less than (\<) 20, 50, and 200 copies per mL at Weeks 48 and 96 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA \< 50 copies per mL; confirmed HIV-1 RNA \>= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.

Time frame:
At Week 48 and 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF
At Week 48: < 20 Copies per mL82.6 (78.3 to 86.4)79.9 (75.4 to 83.9)—
At Week 48: <50 Copies per mL91.2 (87.8 to 93.9)88.7 (85.0 to 91.8)—
At Week 48: <200 Copies per mL93.1 (90.0 to 95.5)91.7 (88.4 to 94.4)—
At Week 96: <20 Copies per mL73.2 (68.3 to 77.7)—78.4 (73.2 to 82.9)
At Week 96: <50 Copies per mL85.1 (81.0 to 88.6)—93.8 (90.4 to 96.3)
At Week 96: <200 Copies per mL86.7 (82.8 to 90.1)—96.9 (94.2 to 98.6)
SecondaryChange From Baseline in log10 HIV-1 RNA Levels at Week 48

Change from baseline in log10 HIV-1 RNA levels were reported.

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · log10 HIV-1 RNA copies per mL
Change From Baseline in log10 HIV-1 RNA Levels at Week 48
log10 HIV-1 RNA copies per mLD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in log10 HIV-1 RNA Levels at Week 48-2.95 ± 0.044-2.91 ± 0.044
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = = 0.437 · Least square mean difference: -0.05 · 95% CI -0.171 to 0.074
SecondaryChange From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48

The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed.

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · Cells per millimeter cube (cells/mm^3)
Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48
Cells per millimeter cube (cells/mm^3)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48190.49 ± 10.472172.01 ± 10.458
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = = 0.213 · Ls mean difference: 18.48 · 95% CI -10.595 to 47.550
SecondaryChange From Baseline in Serum Creatinine at Week 48

Change from baseline in serum creatinine at Week 48 was reported.

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Serum Creatinine at Week 48
milligram per deciliter (mg/dL)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Serum Creatinine at Week 480.05 ± 0.0060.09 ± 0.006
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = < 0.001 · Ls mean difference: -0.04 · 95% CI -0.05 to -0.02
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48

Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR \[\>=90 mL/min\]); Stage 2 (Mild CKD \[60 to 90 mL/min\]); Stage 3 (Moderate CKD \[30 to 59mL/min\]); Stage 4 (Severe CKD \[15 to 29 mL/min\]); Stage 5 (End Stage CKD \[\<15 mL/min\]). The eGFRcr was assessed by calculating serum creatinine (Scr) using the equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144\*(Scr/0.7)\^-0.329\*0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144\*(Scr/0.7)\^-1.209\*0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-0.411\*0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-1.209\*0.993\^age (Scr \>0.9 mg/dL) for male participants.

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48-6.04 ± 0.551-9.16 ± 0.559
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = < 0.001 · Ls mean difference: 3.12 · 95% CI 1.57 to 4.66
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48

Change from baseline in eGFRcr by cockcroft-gault formula at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female.

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · milliliter per minute (mL/min)
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48
milliliter per minute (mL/min)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48-5.16 ± 0.790-11.20 ± 0.802
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = < 0.001 · Ls mean difference: 6.04 · 95% CI 3.83 to 8.25
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48

Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) \>= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[\* 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L).

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 485.32 ± 0.5252.92 ± 0.532
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = = 0.001 · Ls mean difference: 2.40 · 95% CI 0.93 to 3.87
SecondaryPercentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 48

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Up to Weeks 48
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 48
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Grade 3 AEs4.74.4
Grade 4 AEs0.61.7
SAEs4.75.8
Premature discontinuations due to AEs1.94.4
SecondaryChange From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48

Change from baseline in UPCR at Week 48 was reported.

Time frame:
Baseline and Week 48
Reported as:
Median · milligram per gram (mg/g)
Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48
milligram per gram (mg/g)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48-15.72 ± -748.1-10.53 ± -903.0
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · Wilcoxon rank sum test · p = = 0.033
SecondaryChange From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48

Change from baseline in UACR at Week 48 was reported.

Time frame:
Baseline and Week 48
Reported as:
Median · mg/g
Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48
mg/gD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48-0.58 ± -226.5-0.15 ± -640.4
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · Wilcoxon rank sum test · p = = 0.033
SecondaryChange From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48

Change from baseline in URBPCR at Week 48 were reported.

Time frame:
Baseline and Week 48
Reported as:
Median · microgram per gram (mcg/g)
Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48
microgram per gram (mcg/g)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 487.00 ± -1555.735.02 ± -700.7
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · Wilcoxon rank sum test · p = < 0.001
SecondaryChange From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48

Change from baseline in UB2MGCR at Week 48 were reported.

Time frame:
Baseline and Week 48
Reported as:
Median · mcg/g
Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48
mcg/gD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48-30.42 ± -11818.618.36 ± -2440.5
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · Wilcoxon rank sum test · p = < 0.001
SecondaryPercent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48

Percent change from baseline in FEPO4 at Week 48 was reported.

Time frame:
Baseline and Week 48
Reported as:
Median · Percent change
Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48
Percent changeD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 4816.00 ± -87.322.55 ± -90.1
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · Wilcoxon rank sum test · p = = 0.147
SecondaryArea Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir

AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post-dose.

Time frame:
0 to 24 hours post dose
Reported as:
Mean · hours*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir
hours*nanogram per milliliter (h*ng/mL)Darunavir 800 mg [D/C/F/TAF]
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir87909.3282 ± 20232.09905
SecondaryPredose (Trough) Plasma Concentration (C0h) of Darunavir

C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.

Time frame:
30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Predose (Trough) Plasma Concentration (C0h) of Darunavir
nanogram per milliliter (ng/mL)Darunavir 800 mg [D/C/F/TAF (Test)]
Predose (Trough) Plasma Concentration (C0h) of Darunavir1898.9100 ± 758.83837
SecondaryArea Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide

The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.

Time frame:
30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide
h*ng/mLTenofovir Alafenamide 10 mg [D/C/F/TAF (Test)]
Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide132.3117 ± 40.87742
SecondaryPlasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide

C0-2h is defined as the plasma concentrations 2 hours after dosing.

Time frame:
0 to 2 hours post dose
Reported as:
Mean · ng/mL
Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide
ng/mLTenofovir Alafenamide 10 mg [D/C/F/TAF (Test)]
Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide11.9785 ± 11.86104
SecondaryPercent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)

The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from baseline in hip and spine BMD was assessed.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)
Percent changeD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Hip region BMD (Week 24)0.29 ± 0.248-1.66 ± 0.269
Spine region BMD (Week 24)-1.34 ± 0.285-3.43 ± 0.309
Hip region BMD (Week 48)0.17 ± 0.322-2.69 ± 0.342
Spine region BMD (Week 48)-0.68 ± 0.402-2.38 ± 0.428
Statistical analysis
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = < 0.001 · Ls mean difference: 1.95 · 95% CI 1.227 to 2.678
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = < 0.001 · Ls mean difference: 2.86 · 95% CI 1.934 to 3.791
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = < 0.001 · Ls mean difference: 2.09 · 95% CI 1.259 to 2.919
  • D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) vs DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) · ANCOVA · p = = 0.004 · Ls mean difference: 1.70 · 95% CI 0.539 to 2.858
SecondaryChange From Baseline in BMD T-score of Hip and Spine

BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · BMD T-score
Change From Baseline in BMD T-score of Hip and Spine
BMD T-scoreD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Hip region BMD T-score (Week 24)0.019 ± 0.0180-0.109 ± 0.0157
Spine region BMD T-score (Week 24)-0.121 ± 0.0259-0.322 ± 0.0307
Hip region BMD T-score (Week 48)0.015 ± 0.0213-0.177 ± 0.0225
Spine region BMD T-score (Week 48)-0.061 ± 0.0390-0.225 ± 0.0386
SecondaryChange From Baseline in Alkaline Phosphatase (ALP) Levels at Weeks 24 and 48

Change from baseline in ALP at Weeks 24 and 48 was reported.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · Units per liter (U/L)
Change From Baseline in Alkaline Phosphatase (ALP) Levels at Weeks 24 and 48
Units per liter (U/L)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Week 24-3.2 ± 1.1712.0 ± 1.74
Week 48-1.1 ± 1.2915.1 ± 2.00
SecondaryChange From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Weeks 24 and 48

Change from baseline in serum P1NP at Weeks 24 and 48 were reported.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · microgram per liter (mcg/L)
Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Weeks 24 and 48
microgram per liter (mcg/L)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Week 241.892 ± 1.375424.679 ± 2.0956
Week 480.065 ± 1.642824.251 ± 2.6337
SecondaryChange From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Weeks 24 and 48

Change from baseline in serum CTX at Weeks 24 and 48 were reported.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · mcg/L
Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Weeks 24 and 48
mcg/LD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Week 240.047 ± 0.01650.283 ± 0.0251
Week 480.046 ± 0.01740.226 ± 0.0234
SecondaryChange From Baseline in Levels of Parathyroid Hormone (PTH) at Weeks 24 and 48

Change from baseline in PTH at Weeks 24 and 48 were reported.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · Picomol per liter (pmol/L)
Change From Baseline in Levels of Parathyroid Hormone (PTH) at Weeks 24 and 48
Picomol per liter (pmol/L)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Week 240.113 ± 0.21710.777 ± 0.2401
Week 48-0.004 ± 0.22320.633 ± 0.2155
SecondaryChange From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48

Change from baseline in 25-OH Vitamin D levels at Week 24 and 48 were reported.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · nanomol per liter (nmol/L)
Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48
nanomol per liter (nmol/L)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)
Week 2412.7 ± 2.7622.1 ± 3.76
Week 4816.9 ± 2.8428.3 ± 3.15
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach

Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 96), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 96), 3) no viral load data in the Week 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.

Time frame:
At Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach85.1 ± 81.094.2 ± 90.8
SecondaryChange From Reference in log10 HIV-1 RNA Levels at Week 96

Change from reference in log10 HIV-1 RNA levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for Test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Least squares mean · log10 HIV-1 RNA copies per mL
Change From Reference in log10 HIV-1 RNA Levels at Week 96
log10 HIV-1 RNA copies per mLD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in log10 HIV-1 RNA Levels at Week 96-2.72 ± 0.0614-0.0027 ± 0.0131
SecondaryChange From Reference in CD4+ Cell Count at Week 96

The immunologic change was determined by changes in cluster of differentiation (CD4+) cell count. Change from reference in CD4+ cell count at Week 96 was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Least squares mean · cells/mm^3
Change From Reference in CD4+ Cell Count at Week 96
cells/mm^3D/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in CD4+ Cell Count at Week 96228.85 ± 11.95127.01 ± 9.522
SecondaryPercentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability

Treatment adherence assessed by drug accountability (based on pill count) from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study. Adherent participants were defined as having an adherence \>95% as assessed by drug accountability.

Time frame:
Baseline to Switch and switch to EOE to Open-Label D/C/F/TAF (Up to 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF
Baseline to Switch (double-blind treatment)87.282.6—
Switch to End of Extension (open-label D/C/F/TAF)92.2—88.7
SecondaryPercentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 96

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Up to Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 96
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Grade 3 AEs11.63.7
Grade 4 AEs0.81.4
SAEs10.82.7
Premature discontinuations due to AEs2.80.3
SecondaryChange From Reference in Serum Creatinine

Change from reference in serum creatinine was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mg/dL
Change From Reference in Serum Creatinine
mg/dLD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Serum Creatinine0.045 ± -0.25-0.034 ± -0.71
SecondaryChange From Reference in eGFRcr by CKD-EPI Formula

Change from reference in eGFRcr was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD). The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144 \* (Scr/0.7)\^-0.329 \* 0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144 \* (Scr/0.7)\^-1.209 \* 0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141 x (Scr/0.9)\^-0.411 x 0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141 \* (Scr/0.9)\^-1.209 x 0.993\^age (Scr \>0.9 mg/dL) for male participants. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mL/min/1.73 m^2
Change From Reference in eGFRcr by CKD-EPI Formula
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in eGFRcr by CKD-EPI Formula-5.6 ± -332.3 ± -29
SecondaryChange From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula

Change from reference in eGFRcr by cockcroft-gault formula was reported. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mL/min
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula
mL/minD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula-5.2 ± -734.6 ± -47
SecondaryChange From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula

Change from reference in eGFRcyst was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[x 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L). Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mL/min/1.73 m^2
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula4.4 ± -140 ± -12
SecondaryChange From Reference in UPCR

Change from reference in UPCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mg/g
Change From Reference in UPCR
mg/gD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in UPCR-15.46 (-728.7 to 197.9)-1.40 (-705.7 to 289.2)
SecondaryChange From Reference in UACR

Change from reference in UACR at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mg/g
Change From Reference in UACR
mg/gD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in UACR-0.70 ± -288.1-0.49 ± -294.5
SecondaryChange From Reference in URBPCR

Change from reference in URBPCR at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mcg/g
Change From Reference in URBPCR
mcg/gD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in URBPCR13.70 ± -1555.1-35.53 ± -108886.3
SecondaryChange From Reference in UB2MGCR

Change from reference in UB2MGCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mcg/g
Change From Reference in UB2MGCR
mcg/gD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in UB2MGCR-27.04 ± -11704.6-40.53 ± -111778.9
SecondaryPercent Change From Reference in Urine FEPO4

Percent change from reference in FEPO4 at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · Percent change in urine FEPO4
Percent Change From Reference in Urine FEPO4
Percent change in urine FEPO4D/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Percent Change From Reference in Urine FEPO418.52 ± -84.2-7.51 ± -83.5
SecondaryPercent Change From Reference in Hip and Spine BMD

The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DEXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · Percent change in BMD
Percent Change From Reference in Hip and Spine BMD
Percent change in BMDD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Hip region BMD-0.2565 ± 0.355990.5467 ± 0.38512
Spine region BMD-0.9349 ± 0.445990.4829 ± 0.39270
SecondaryChange From Reference in BMD T-score of Hip and Spine at Week 96

BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · BMD T-score
Change From Reference in BMD T-score of Hip and Spine at Week 96
BMD T-scoreD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Hip region BMD T-score-0.016 ± 0.02450.025 ± 0.0272
Spine region BMD T-score-0.090 ± 0.04070.034 ± 0.0355
SecondaryChange From Reference in ALP Levels

Change from reference in ALP levels at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · U/L
Change From Reference in ALP Levels
U/LD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in ALP Levels-0.9 ± 1.23-9.7 ± 1.55
SecondaryChange From Reference in Levels of Serum P1NP

Change from reference in serum P1NP levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · mcg/L
Change From Reference in Levels of Serum P1NP
mcg/LD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Levels of Serum P1NP2.817 ± 1.7140-11.963 ± 1.7636
SecondaryChange From Reference in Levels of Serum CTX

Change from reference in serum CTX levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · mcg/L
Change From Reference in Levels of Serum CTX
mcg/LD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Levels of Serum CTX0.041 ± 0.0190-0.162 ± 0.0190
SecondaryChange From Reference in Levels of PTH

Change from reference in PTH levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · pmol/L
Change From Reference in Levels of PTH
pmol/LD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Levels of PTH-0.290 ± 0.2078-1.283 ± 0.2483
SecondaryChange From Reference in Levels of 25-OH Vitamin D

Change from reference in 25-OH Vitamin D were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · nmol/L
Change From Reference in Levels of 25-OH Vitamin D
nmol/LD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Levels of 25-OH Vitamin D21.3 ± 2.45-10.3 ± 2.87
SecondaryPercentage of Participants With HIV RNA <50, <20, and <200 Copies/mL Post-week 96 to End of Extension

Percentage of participants with HIV RNA \<50, \<20, and \<200 copies/mL post Week 96 to end of extension were reported.

Time frame:
Week 96 to end of extension (up to 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With HIV RNA <50, <20, and <200 Copies/mL Post-week 96 to End of Extension
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Week 96 + 6 months (<50 copies/mL)97.7 (95.3 to 99.1)96.3 (93.4 to 98.1)
Week 96 + 12 months (<50 copies/mL)99.0 (96.3 to 99.9)96.7 (93.4 to 98.7)
Week 96 + 18 months (<50 copies/mL)98.1 (94.6 to 99.6)98.2 (94.8 to 99.6)
Week 96 + 24 months (<50 copies/mL)97.5 (91.4 to 99.7)95.7 (89.2 to 98.8)
Week 96 + 30 months (<50 copies/mL)94.7 (85.4 to 98.9)91.4 (81.0 to 97.1)
Week 96 + 36 months (<50 copies/mL)100.0 (82.4 to 100.0)68.8 (41.3 to 89.0)
Week 96 + 6 months (<20 copies/mL)85.8 (81.4 to 89.5)88.2 (83.9 to 91.6)
Week 96 + 12 months (<20 copies/mL)89.7 (84.5 to 93.6)91.6 (87.0 to 94.9)
Week 96 + 18 months (<20 copies/mL)92.4 (87.1 to 96.0)92.8 (87.8 to 96.2)
Week 96 + 24 months (<20 copies/mL)90.1 (81.5 to 95.6)87.0 (78.3 to 93.1)
Week 96 + 30 months (<20 copies/mL)89.5 (78.5 to 96.0)84.5 (72.6 to 92.7)
Week 96 + 36 months (<20 copies/mL)94.7 (74.0 to 99.9)62.5 (35.4 to 84.8)
Week 96 + 6 months (<200 copies/mL)99.7 (98.2 to 100.0)99.3 (97.6 to 99.9)
Week 96 + 12 months (<200 copies/mL)100.0 (98.1 to 100.0)99.5 (97.4 to 100)
Week 96 + 18 months (<200 copies/mL)98.7 (95.5 to 99.8)98.2 (94.8 to 99.6)
Week 96 + 24 months (<200 copies/mL)97.5 (91.4 to 99.7)97.8 (92.4 to 99.7)
Week 96 + 30 months (<200 copies/mL)96.5 (87.9 to 99.6)98.3 (90.8 to 100.0)
Week 96 + 36 months (<200 copies/mL)100.0 (82.4 to 100.0)87.5 (61.7 to 98.4)
SecondaryPercentage of Participants With Protocol-defined Virologic Failure (PDVF)

Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).

Time frame:
From Baseline up to Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF
Participants who met PDVF (Baseline - Week 96)4.1——
Virologic non-response (Baseline - Week 96)0.6——
Virologic rebound (Baseline-Week 96)0.3——
Viremic at final time point (Baseline-Week 96)0.6——
Participants who met PDVF (Baseline - Switch)—4.4—
Virologic non-response (Baseline - Switch)—0—
Virologic rebound (Baseline - Switch)—3.9—
Viremic at final time point (Baseline - Switch)—0.6—
Participants who met PDVF (Switch - Week 96)——1.1
Virologic non-response (Switch - Week 96)——0
Virologic rebound (Switch - Week 96)——1.1
Viremic at final time point (Switch - Week 96)——0
SecondaryPercentage of Participants With PDVF Post-week 96 to End of Extension

Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).

Time frame:
Week 96 to end of extension (up to 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With PDVF Post-week 96 to End of Extension
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Participants who met PDVF1.02.1
Virologic non-response00
Virologic rebound1.01.4
Viremic at final time point00.7
SecondaryPercentage of Participants With Non-PDVF by Kaplan-Meier Estimates

Percentage of participants with non-PDVF by Kaplan-Meier Estimates were reported. PDVF was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).

Time frame:
From Week 96 to end of extension (up to 2 years and 6 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-PDVF by Kaplan-Meier Estimates
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Week 96100 (100 to 100)100 (100 to 100)
Week 96 + 6 months99.6 (97.2 to 99.9)99.2 (97.0 to 99.8)
Week 96 + 12 months99.6 (97.2 to 99.9)99.2 (97.0 to 99.8)
Week 96 + 18 months98.6 (94.0 to 99.7)97.8 (94.1 to 99.2)
Week 96 + 24 months97.3 (91.0 to 99.2)97.8 (94.1 to 99.2)
Week 96 + 30 months97.3 (91.0 to 99.2)92.5 (79.8 to 97.3)
SecondaryPercentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates

Percentage of participants with time to treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic failure or having discontinued for reasons other than alternate access to D/C/F/TAF (or other ARVs).

Time frame:
From Week 96 to end of extension (up to 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Week 96100 (100 to 100)100 (100 to 100)
Week 96 + 6 months98.9 (96.5 to 99.6)97.4 (94.5 to 98.7)
Week 96 + 12 months95.6 (91.7 to 97.7)94.1 (90.2 to 96.5)
Week 96 + 18 months90.6 (84.9 to 94.2)89.5 (84.3 to 93.0)
Week 96 + 24 months87.1 (79.8 to 91.8)86.4 (80.0 to 90.9)
Week 96 + 30 months84.8 (75.8 to 90.6)79.1 (68.9 to 86.3)
Week 96 + 36 months84.8 (75.8 to 90.6)—
SecondaryCD4+ Cell Count Post-Week From 96 to End of Extension

The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.

Time frame:
Week 96 to end of extension (up to 3 years)
Reported as:
Mean · cells/mm^3
CD4+ Cell Count Post-Week From 96 to End of Extension
cells/mm^3D/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Week 96 + 6 months790.2 ± 17.23749.7 ± 16.44
Week 96 + 12 months779.4 ± 22.45774.3 ± 21.91
Week 96 + 18 months789.8 ± 23.43758.4 ± 23.25
Week 96 + 24 months781.9 ± 37.77784.1 ± 30.78
Week 96 + 30 months741.6 ± 37.12736.7 ± 37.47
Week 96 + 36 months784.7 ± 69.74778.4 ± 86.59
SecondaryNumber of Participants With ARV Resistance

Number of participants with DRV, FTC, TDF/TAF resistance were reported.

Time frame:
Baseline to end of extension (up to 4 years)
Reported as:
Count of participants · Participants
Number of Participants With ARV Resistance
ParticipantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF
DRV resistance-associated mutations (RAMs)000
TFV RAMs000
FTC RAMs212
SecondaryPercentage of Participants With Grade 3 and 4 AEs, SAEs, and Premature Discontinuations Due to Adverse Events Post-Week 96 to End of Extension

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From Week 96 to end of extension (up to 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 3 and 4 AEs, SAEs, and Premature Discontinuations Due to Adverse Events Post-Week 96 to End of Extension
percentage of participantsD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Switch to D/C/F/TAF
Grade 3 AEs3.55.2
Grade 4 AEs01.3
SAEs3.24.8
Premature discontinuations due to AEs1.01.3

Adverse events

Collected over Up to 60 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
D/C/F/TAF+ FTC/TDF (Test)0/362 (0%)47/362 (13%)284/362 (78.5%)
DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)1/363 (0.3%)36/363 (9.9%)252/363 (69.4%)
Switch to D/C/F/TAF Group1/322 (0.3%)21/322 (6.5%)137/322 (42.5%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventD/C/F/TAF+ FTC/TDF (Test)DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF Group
AppendicitisInfections and infestations3/3622/3631/322
Hepatitis AInfections and infestations3/3623/3632/322
PneumoniaInfections and infestations3/3621/3630/322
Suicide AttemptPsychiatric disorders0/3623/3631/322
ErysipelasInfections and infestations0/3620/3632/322
Suicidal IdeationPsychiatric disorders1/3621/3632/322
Anogenital DysplasiaGastrointestinal disorders2/3621/3630/322
Anal AbscessInfections and infestations2/3621/3630/322
Anogenital WartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3622/3630/322
RashSkin and subcutaneous tissue disorders0/3622/3630/322
Most frequent other events
Showing 10 of 23
Most frequent other events
EventD/C/F/TAF+ FTC/TDF (Test)DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Switch to D/C/F/TAF Group
DiarrhoeaGastrointestinal disorders89/36272/36318/322
NasopharyngitisInfections and infestations64/36238/36319/322
HeadacheNervous system disorders56/36238/36311/322
NauseaGastrointestinal disorders34/36246/3638/322
SyphilisInfections and infestations41/36225/36324/322
Upper Respiratory Tract InfectionInfections and infestations40/36230/36326/322
RashSkin and subcutaneous tissue disorders37/36225/3639/322
PharyngitisInfections and infestations31/36219/3637/322
Back PainMusculoskeletal and connective tissue disorders31/36210/36316/322
OsteopeniaMusculoskeletal and connective tissue disorders19/36229/3630/322

Baseline characteristics

The intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.

Age, Continuous
Age, Continuous(years)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Total
Median34 (19 to 61)34 (18 to 71)34.0 (18 to 71)
Age, Customized
Age, Customized(Participants)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Total
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)362362724
From 65 to 84 years011
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Total
Female444185
Male318322640
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)D/C/F/TAF (Test) (Baseline to End of Extension [EOE])DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)Total
Asian4711
Black or African American404080
Hispanic or Latino413879
Other191837
White Non-Hispanic258260518
08

Study locations

81 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Bakersfield, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • North Hollywood, California, United States
  • San Francisco, California, United States
  • Washington, District of Columbia, United States
  • Fort Pierce, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • West Palm Beach, Florida, United States
  • Savannah, Georgia, United States
  • Boston, Massachusetts, United States
  • Springfield, Massachusetts, United States
  • Berkley, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Hillsborough, New Jersey, United States
  • Newark, New Jersey, United States
  • Somers Point, New Jersey, United States
  • Santa Fe, New Mexico, United States
  • Manhasset, New York, United States
  • Chapel Hill, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Antwerpen, Belgium
  • Brussels, Belgium
  • Brussel, Belgium
  • Gent, Belgium
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Clamart, France
  • Le Kremlin Bicetre, France
  • Lyon, France
  • Marseille, France
  • Montpellier, France
  • Nantes, France
  • Paris, France
  • Strasbourg, France
  • Tourcoing, France
  • Berlin, Germany
  • Bonn, Germany
  • Essen, Germany
  • Frankfurt, Germany
  • Freiburg im Breisgau, Germany
  • Hamburg, Germany
  • Hannover, Germany
  • Köln, Germany
  • München, Germany
  • Bydgoszcz, Poland
  • Chorzow, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • San Juan, Puerto Rico
  • Ekaterinburg, Russian Federation
  • Krasnodar, Russian Federation
  • Orel, Russian Federation
  • Saint Petersburg, Russian Federation
  • Saratov, Russian Federation
  • Smolensk, Russian Federation
  • Tolyatti, Russian Federation
  • Voronezh, Russian Federation
  • Alicante, Spain
  • Badalona, Spain
  • Barcelona, Spain
  • Cordoba, Spain
  • Elche, Spain
  • Madrid, Spain
  • Santiago de Compostela, Spain
  • Sevilla, Spain
  • Valencia, Spain
  • Brighton, United Kingdom
  • Bristol, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Ackaert O, McDougall D, Perez-Ruixo C, Perez-Ruixo JJ, Jezorwski J, Crauwels HM. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). AAPS J. 2021 Jun 7;23(4):82. doi: 10.1208/s12248-021-00607-8. PubMed 34100149 ↗
  • Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Opsomer M; AMBER study group. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2020 Apr 1;34(5):707-718. doi: 10.1097/QAD.0000000000002463. PubMed 31833849 ↗
  • Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S; AMBER and EMERALD Study Groups. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21. PubMed 31516033 ↗
  • Rashbaum B, Spinner CD, McDonald C, Mussini C, Jezorwski J, Luo D, Van Landuyt E, Brown K, Wong EY. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive patients with HIV-1: subgroup analyses of the phase 3 AMBER study. HIV Res Clin Pract. 2019 Feb;20(1):24-33. doi: 10.1080/15284336.2019.1608714. Epub 2019 May 29. PubMed 31303147 ↗
  • Eron JJ, Orkin C, Gallant J, Molina JM, Negredo E, Antinori A, Mills A, Reynes J, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Vanveggel S, Opsomer M; AMBER study group. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018 Jul 17;32(11):1431-1442. doi: 10.1097/QAD.0000000000001817. PubMed 29683855 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Mar 2017, 19 months.

Results were first posted in Sep 2018, 1 year 6 months after primary completion. A results delay was requested in Mar 2018.

Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 19 months is below that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2015
First posted
Apr 30, 2015
StartActual
Jul 6, 2015
Primary completionActual
Mar 2, 2017
CompletionActual
Sep 30, 2020
Results delay requested
Mar 2, 2018
Results first posted
Sep 14, 2018
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02431247
Responsible party
Sponsor
First posted
Apr 30, 2015
Start date
Jul 6, 2015
Primary completion
Mar 2, 2017
Completion
Sep 30, 2020
Results posted
Sep 14, 2018
Last update
Sep 28, 2022

Study contacts

Janssen Sciences Ireland UC Clinical Trial
study director · Janssen Sciences Ireland UC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion